Compass Financial Management LLC bought a new stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) in the second quarter, HoldingsChannel reports. The institutional investor bought 4,260 shares of the exchange traded fund’s stock, valued at approximately $733,000.
Other institutional investors have also added to or reduced their stakes in the company. Avoro Capital Advisors LLC purchased a new position in shares of SPDR S&P Biotech ETF during the 4th quarter worth $256,053,000. Bank of America Corp DE increased its stake in shares of SPDR S&P Biotech ETF by 13.3% in the 1st quarter. Bank of America Corp DE now owns 14,518,027 shares of the exchange traded fund’s stock worth $1,854,388,000 after purchasing an additional 1,700,851 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of SPDR S&P Biotech ETF by 75.7% in the 4th quarter. Wells Fargo & Company MN now owns 3,566,265 shares of the exchange traded fund’s stock worth $434,835,000 after purchasing an additional 1,536,122 shares in the last quarter. OMERS ADMINISTRATION Corp raised its holdings in SPDR S&P Biotech ETF by 42,425.2% in the 4th quarter. OMERS ADMINISTRATION Corp now owns 1,190,707 shares of the exchange traded fund’s stock worth $145,147,000 after purchasing an additional 1,187,907 shares during the period. Finally, Morgan Stanley raised its holdings in SPDR S&P Biotech ETF by 8.3% in the 4th quarter. Morgan Stanley now owns 11,491,683 shares of the exchange traded fund’s stock worth $1,401,181,000 after purchasing an additional 882,718 shares during the period.
SPDR S&P Biotech ETF Stock Performance
NYSEARCA XBI opened at $165.73 on Monday. The company has a market capitalization of $10.82 billion, a PE ratio of 11.47 and a beta of 0.83. The business’s fifty day moving average is $153.99 and its 200 day moving average is $137.76. SPDR S&P Biotech ETF has a fifty-two week low of $88.60 and a fifty-two week high of $169.68.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Recommended Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
